Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
| 対象疾患 | Major Depressive Disorder, Depression |
|---|---|
| 相 | 第3相 |
| スポンサー | Levomecor Inc. |
| ステータス | 早期終了 |
| 参加者数 | 27 名 |
| 介入（薬剤） | REL-1017 |
| 開始日 | 2023年8月17日 |
| 完了日 | 2024年12月19日 |
| 結果公開日 | 2026年7月10日 |
概要
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Change From Baseline to Day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
| REL-1017 | -16.8 ± 7.62 Scores on a scale (MADRS10) |
|---|---|
| Placebo | -13.4 ± 9.55 Scores on a scale (MADRS10) |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital